We are live on ! Find out more
LAB icon

Standard BioTools

145 hedge funds and large institutions have $719M invested in Standard BioTools in 2024 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 47 increasing their positions, 13 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

311,000% more call options, than puts

Call options by funds: $3.11M | Put options by funds: $1K

519% more capital invested

Capital invested by funds: $116M → $719M (+$603M)

454% more first-time investments, than exits

New positions opened: 72 | Existing positions closed: 13

262% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 13

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

69% more funds holding

Funds holding: 86145 (+59)

25.84% more ownership

Funds ownership: 65.62%91.46% (+26%)

Holders
145
Holders Change
+59
Holders Change %
+68.6%
% of All Funds
2.09%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
72
Increased
47
Reduced
13
Closed
13
Calls
$3.11M
Puts
$1K
Net Calls
+$3.11M
Net Calls Change
+$3.08M
Name Holding Trade Value Shares
Change
Change in
Stake
DTL
151
Dynamic Technology Lab
Singapore
-$55K -24,677 Closed
Prudential Financial
152
Prudential Financial
New Jersey
-$47.7K -21,600 Closed
NAM
153
Nexpoint Asset Management
Texas
-$34.1K -15,447 Closed
Acadian Asset Management
154
Acadian Asset Management
Massachusetts
-$19K -8,868 Closed
SNB
155
Security National Bank
Nebraska
-$1.25K -565 Closed
ASN
156
Advisory Services Network
Georgia
-$1.1K -500 Closed
Simplex Trading
157
Simplex Trading
Illinois
-$1.06K -438 Closed
AssetMark Inc
158
AssetMark Inc
California
-$137 -62 Closed

LAB Hedge Fund Activity: Q1 2024 in Review

145 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2024, worth a combined $719M — up 519% from $116M a quarter earlier.

Buyers outnumbered sellers: 72 funds opened new LAB positions and 13 closed out — a net gain of 59 holders — while 47 added to existing stakes and 13 trimmed.

The largest buyer was Casdin Capital, adding an estimated $147M. The largest seller was Caligan Partners, exiting entirely with an estimated $15.6M sold.

  • 145 institutional investors held Standard BioTools (LAB) as of Q1 2024, up from 86 in Q4 2023.
  • Funds reported $719M of Standard BioTools stock for Q1 2024, up 519% quarter-over-quarter.
  • 72 funds opened new Standard BioTools positions in Q1 2024 and 13 closed out, a net change of +59 holders.
  • The largest Standard BioTools buyer in Q1 2024 was Casdin Capital, an estimated $147M added.
  • The largest Standard BioTools seller in Q1 2024 was Caligan Partners, an estimated $15.6M sold.

Based on aggregated 13F filings for Q1 2024.